Behind the scenes in Eliquis drama
| June 24, 2013 | Cardiovascular Business | Heart Rhythm

The June issue of Pharmaceuticals Monthly explores the delay in the approval of apixaban (Eliquis) by the FDA. “Apixaban shows how a review that seems, on its face, like it should be a quick and clean affair can become derailed by issues that, but for the agency’s own public disclosures post-approval, would never see the light of day,” according to the article.

Eliquis approval delayed by fraud, dispensing errors in pivotal trial

Related Content

2 out of 5 AFib patients develop heart failure later in life
FDA grants fast track designation to new drug for Friedreich's ataxia cardiomyopathy
FDA grants anticoagulant its orphan drug designation for treating patients with implanted devices
Biosense Webster takes key step toward FDA approval for Varipulse PFA system
Cardiologists are first in world to remove unstable Watchman devices with FDA-cleared retrieval system
Heart issues more common in adults who drink soda, other sweetened beverages

Around the web

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Radiology Business
Philips launches new AI-enabled CT scanner aimed at cardiology at ECR 2024

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Design by Adaptive Theme
Trimed Popup
Trimed Popup